Your browser is no longer supported. Please, upgrade your browser.
CTMX [NASD]
CytomX Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.23 Insider Own0.30% Shs Outstand60.97M Perf Week-14.42%
Market Cap503.73M Forward P/E- EPS next Y-1.74 Insider Trans-34.98% Shs Float56.52M Perf Month5.31%
Income-60.60M PEG- EPS next Q-0.36 Inst Own75.30% Short Float10.94% Perf Quarter-7.40%
Sales66.70M P/S7.55 EPS this Y68.40% Inst Trans27.05% Short Ratio6.09 Perf Half Y14.99%
Book/sh2.40 P/B3.39 EPS next Y-21.40% ROA-15.40% Target Price13.19 Perf Year-42.91%
Cash/sh6.36 P/C1.28 EPS next 5Y-0.90% ROE-80.10% 52W Range6.25 - 15.44 Perf YTD24.12%
Dividend- P/FCF22.00 EPS past 5Y32.00% ROI-69.70% 52W High-46.76% Beta0.70
Dividend %- Quick Ratio4.10 Sales past 5Y67.10% Gross Margin- 52W Low31.52% ATR0.57
Employees144 Current Ratio4.10 Sales Q/Q-67.70% Oper. Margin-92.00% RSI (14)46.83 Volatility7.65% 7.14%
OptionableYes Debt/Eq0.00 EPS Q/Q-195.60% Profit Margin-90.90% Rel Volume0.67 Prev Close8.13
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume1.02M Price8.22
Recom2.10 SMA20-3.70% SMA50-0.28% SMA2009.23% Volume543,361 Change1.11%
Mar-29-21Initiated JP Morgan Overweight $14
Mar-23-21Upgrade Jefferies Hold → Buy
Sep-22-20Downgrade Guggenheim Buy → Neutral
Jun-01-20Downgrade Jefferies Buy → Hold $16 → $10
May-14-20Reiterated H.C. Wainwright Buy $16 → $12
Mar-24-20Upgrade Wedbush Neutral → Outperform
Mar-04-20Initiated Barclays Equal Weight $7
Nov-20-19Initiated Guggenheim Buy
Nov-11-19Downgrade Wedbush Outperform → Neutral $25 → $8
Jun-13-19Initiated Mizuho Buy
May-14-19Initiated Cantor Fitzgerald Overweight $21
Mar-11-19Initiated Barclays Overweight $16
Nov-26-18Initiated Piper Jaffray Overweight $22
Oct-15-18Initiated Goldman Neutral $21
Sep-13-18Initiated H.C. Wainwright Buy $32
Jun-01-18Initiated SunTrust Buy $38
Jan-05-18Initiated Citigroup Buy $40
Sep-08-17Initiated Wedbush Outperform $26
Mar-27-17Initiated H.C. Wainwright Buy $24
Mar-02-17Initiated Instinet Buy $21
May-08-21 01:30PM  
May-06-21 06:05PM  
04:15PM  
03:15PM  
Apr-29-21 08:00AM  
Apr-14-21 04:01PM  
11:42AM  
Mar-24-21 08:00AM  
Mar-02-21 12:00PM  
05:58AM  
Feb-25-21 09:01AM  
Feb-24-21 04:15PM  
Feb-23-21 10:25AM  
Feb-22-21 08:00AM  
Feb-20-21 02:44AM  
Feb-19-21 08:00AM  
Feb-17-21 08:00AM  
Feb-04-21 08:00AM  
Feb-03-21 08:19AM  
08:00AM  
Jan-26-21 08:00AM  
Jan-20-21 09:50PM  
Jan-19-21 04:35PM  
08:00AM  
Jan-07-21 08:00AM  
Dec-24-20 10:10AM  
Dec-22-20 04:05PM  
12:58AM  
Dec-03-20 08:00AM  
Nov-11-20 04:01PM  
Nov-07-20 08:40AM  
Nov-06-20 03:01PM  
Nov-05-20 08:00PM  
04:15PM  
04:15PM  
08:00AM  
Oct-29-20 12:34PM  
08:00AM  
Oct-09-20 08:32AM  
Oct-06-20 05:41PM  
04:10PM  
Sep-18-20 08:00AM  
Sep-02-20 08:00AM  
Aug-24-20 09:23AM  
Aug-06-20 04:15PM  
Aug-04-20 08:00AM  
Jul-30-20 12:33PM  
Jul-28-20 08:00AM  
Jul-20-20 04:03PM  
01:00PM  
12:40PM  
11:40AM  
11:00AM  
09:48AM  
08:50AM  
07:30AM  
06:20AM  
12:20AM  
Jul-18-20 03:45PM  
01:35PM  
Jul-17-20 11:24PM  
01:30PM  
01:00PM  
12:32PM  
11:50AM  
11:21AM  
Jul-16-20 03:45PM  
01:55PM  
01:53PM  
12:12PM  
12:10PM  
11:30AM  
10:11AM  
09:52AM  
09:39AM  
08:00AM  
Jul-15-20 09:55AM  
09:25AM  
Jul-14-20 12:23PM  
11:00AM  
10:24AM  
09:24AM  
03:49AM  
Jul-13-20 10:15AM  
09:50AM  
01:30AM  
Jul-12-20 11:00AM  
Jul-10-20 11:47PM  
06:57PM  
05:30PM  
01:30PM  
01:00PM  
11:34AM  
Jul-09-20 04:20PM  
03:15PM  
Jul-08-20 06:50PM  
01:50PM  
01:15PM  
01:10PM  
Jul-07-20 05:30PM  
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCarthy Sean A.President and CEOMar 31Option Exercise1.13100,000113,390306,894Apr 02 05:37 PM
McCarthy Sean A.President and CEOMar 31Sale7.49100,000749,470206,894Apr 02 05:37 PM
McCarthy Sean A.President and CEODec 23Option Exercise1.13100,000113,390206,894Dec 28 07:52 PM
McCarthy Sean A.President and CEOSep 21Option Exercise6.6120,500135,601105,964Sep 23 04:53 PM
McCarthy Sean A.President and CEOMay 12Option Exercise1.1336,00040,820120,306May 14 04:31 PM
McCarthy Sean A.President and CEOMay 12Sale15.0036,000540,00084,306May 14 04:31 PM